Which has higher earnings and valuation, NYXH or RCEL?

Avita Medical has higher revenue and earnings than Nyxoah. Avita Medical is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $11.33M 5.54 -$101.92M -$2.52 N/A Avita Medical $71.61M 3.37 -$48.59M -$1.44 N/A

Is NYXH or RCEL more profitable?

Avita Medical has a net margin of -56.96% compared to Nyxoah's net margin of -443.16%. Avita Medical's return on equity of 0.00% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -443.16% -178.90% -81.83% Avita Medical -56.96% N/A -78.53%

Does the media favor NYXH or RCEL?

In the previous week, Avita Medical had 1 more articles in the media than Nyxoah. MarketBeat recorded 4 mentions for Avita Medical and 3 mentions for Nyxoah. Nyxoah's average media sentiment score of 0.64 beat Avita Medical's score of 0.49 indicating that Nyxoah is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nyxoah 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avita Medical 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, FOCL or NYXH?

FocalTherics has higher revenue and earnings than Nyxoah. FocalTherics is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FocalTherics $70.53M 2.53 -$29.25M -$0.81 N/A Nyxoah $11.33M 5.54 -$101.92M -$2.52 N/A

Is FOCL or NYXH more profitable?

FocalTherics has a net margin of -56.26% compared to Nyxoah's net margin of -443.16%. FocalTherics' return on equity of -175.45% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -56.26% -175.45% -44.72% Nyxoah -443.16% -178.90% -81.83%

Does the media prefer FOCL or NYXH?

In the previous week, FocalTherics had 10 more articles in the media than Nyxoah. MarketBeat recorded 13 mentions for FocalTherics and 3 mentions for Nyxoah. Nyxoah's average media sentiment score of 0.64 beat FocalTherics' score of 0.15 indicating that Nyxoah is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FocalTherics 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nyxoah 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, NYXH or PDEX?

Pro-Dex has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $11.33M 5.54 -$101.92M -$2.52 N/A Pro-Dex $66.59M 3.21 $8.98M $3.62 18.51

Is NYXH or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to Nyxoah's net margin of -443.16%. Pro-Dex's return on equity of 22.78% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -443.16% -178.90% -81.83% Pro-Dex 16.08% 22.78% 14.30%

Does the media prefer NYXH or PDEX?

In the previous week, Nyxoah and Nyxoah both had 3 articles in the media. Pro-Dex's average media sentiment score of 1.20 beat Nyxoah's score of 0.64 indicating that Pro-Dex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nyxoah 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pro-Dex 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NYXH or CNXU?

In the previous week, Conexeu Sciences had 1 more articles in the media than Nyxoah. MarketBeat recorded 4 mentions for Conexeu Sciences and 3 mentions for Nyxoah. Conexeu Sciences' average media sentiment score of 0.99 beat Nyxoah's score of 0.64 indicating that Conexeu Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nyxoah 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Conexeu Sciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NYXH or INGN?

Nyxoah presently has a consensus target price of $5.26, suggesting a potential upside of 224.81%. Given Nyxoah's higher possible upside, research analysts plainly believe Nyxoah is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nyxoah 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better valuation and earnings, NYXH or INGN?

Inogen has higher revenue and earnings than Nyxoah. Inogen is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $11.33M 5.54 -$101.92M -$2.52 N/A Inogen $348.67M 0.44 -$22.75M -$0.90 N/A

Is NYXH or INGN more profitable?

Inogen has a net margin of -6.94% compared to Nyxoah's net margin of -443.16%. Inogen's return on equity of -13.17% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -443.16% -178.90% -81.83% Inogen -6.94% -13.17% -8.36%

Does the media favor NYXH or INGN?

In the previous week, Inogen had 2 more articles in the media than Nyxoah. MarketBeat recorded 5 mentions for Inogen and 3 mentions for Nyxoah. Nyxoah's average media sentiment score of 0.64 beat Inogen's score of 0.44 indicating that Nyxoah is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nyxoah 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inogen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Nyxoah (NYXH) Competitors

$1.62 +0.04 (+2.53%)

Closing price 04:00 PM Eastern

Extended Trading

$1.62 +0.00 (+0.31%)

As of 07:34 PM Eastern

Compare

NYXH vs. RCEL, FOCL, PDEX, CNXU, and INGN

Should you buy Nyxoah stock or one of its competitors? Nyxoah's main competitors and comparable companies include Avita Medical (RCEL), FocalTherics (FOCL), Pro-Dex (PDEX), Conexeu Sciences (CNXU), and Inogen (INGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Nyxoah compare to Avita Medical?

Nyxoah (NASDAQ:NYXH) and Avita Medical (NASDAQ:RCEL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

In the previous week, Avita Medical had 1 more articles in the media than Nyxoah. MarketBeat recorded 4 mentions for Avita Medical and 3 mentions for Nyxoah. Nyxoah's average media sentiment score of 0.64 beat Avita Medical's score of 0.49 indicating that Nyxoah is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avita Medical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avita Medical has a net margin of -56.96% compared to Nyxoah's net margin of -443.16%. Avita Medical's return on equity of 0.00% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-443.16%	-178.90%	-81.83%
Avita Medical	-56.96%	N/A	-78.53%

Nyxoah has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, Avita Medical has a beta of 1.86, indicating that its stock price is 86% more volatile than the broader market.

Nyxoah currently has a consensus price target of $5.26, suggesting a potential upside of 224.81%. Avita Medical has a consensus price target of $8.25, suggesting a potential upside of 5.10%. Given Nyxoah's higher probable upside, equities analysts plainly believe Nyxoah is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

27.7% of Avita Medical shares are held by institutional investors. 17.1% of Nyxoah shares are held by insiders. Comparatively, 2.2% of Avita Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Avita Medical has higher revenue and earnings than Nyxoah. Avita Medical is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	5.54	-$101.92M	-$2.52	N/A
Avita Medical	$71.61M	3.37	-$48.59M	-$1.44	N/A

Summary

Avita Medical beats Nyxoah on 11 of the 16 factors compared between the two stocks.

How does Nyxoah compare to FocalTherics?

FocalTherics (NASDAQ:FOCL) and Nyxoah (NASDAQ:NYXH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

In the previous week, FocalTherics had 10 more articles in the media than Nyxoah. MarketBeat recorded 13 mentions for FocalTherics and 3 mentions for Nyxoah. Nyxoah's average media sentiment score of 0.64 beat FocalTherics' score of 0.15 indicating that Nyxoah is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FocalTherics	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nyxoah	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

FocalTherics has higher revenue and earnings than Nyxoah. FocalTherics is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.53	-$29.25M	-$0.81	N/A
Nyxoah	$11.33M	5.54	-$101.92M	-$2.52	N/A

FocalTherics has a net margin of -56.26% compared to Nyxoah's net margin of -443.16%. FocalTherics' return on equity of -175.45% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-56.26%	-175.45%	-44.72%
Nyxoah	-443.16%	-178.90%	-81.83%

62.7% of FocalTherics shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by company insiders. Comparatively, 17.1% of Nyxoah shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

FocalTherics has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market. Comparatively, Nyxoah has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

FocalTherics currently has a consensus target price of $7.75, suggesting a potential upside of 62.82%. Nyxoah has a consensus target price of $5.26, suggesting a potential upside of 224.81%. Given Nyxoah's higher probable upside, analysts clearly believe Nyxoah is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

FocalTherics beats Nyxoah on 10 of the 17 factors compared between the two stocks.

How does Nyxoah compare to Pro-Dex?

Nyxoah (NASDAQ:NYXH) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

In the previous week, Nyxoah and Nyxoah both had 3 articles in the media. Pro-Dex's average media sentiment score of 1.20 beat Nyxoah's score of 0.64 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pro-Dex	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.3% of Pro-Dex shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by company insiders. Comparatively, 45.9% of Pro-Dex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pro-Dex has a net margin of 16.08% compared to Nyxoah's net margin of -443.16%. Pro-Dex's return on equity of 22.78% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-443.16%	-178.90%	-81.83%
Pro-Dex	16.08%	22.78%	14.30%

Pro-Dex has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	5.54	-$101.92M	-$2.52	N/A
Pro-Dex	$66.59M	3.21	$8.98M	$3.62	18.51

Nyxoah presently has a consensus price target of $5.26, indicating a potential upside of 224.81%. Pro-Dex has a consensus price target of $70.00, indicating a potential upside of 4.45%. Given Nyxoah's higher possible upside, analysts plainly believe Nyxoah is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Nyxoah has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

Summary

Pro-Dex beats Nyxoah on 11 of the 14 factors compared between the two stocks.

How does Nyxoah compare to Conexeu Sciences?

Nyxoah (NASDAQ:NYXH) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Nyxoah presently has a consensus target price of $5.26, suggesting a potential upside of 224.81%. Conexeu Sciences has a consensus target price of $20.00, suggesting a potential upside of 124.72%. Given Nyxoah's higher possible upside, research analysts plainly believe Nyxoah is more favorable than Conexeu Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Conexeu Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Conexeu Sciences has lower revenue, but higher earnings than Nyxoah. Conexeu Sciences is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	5.54	-$101.92M	-$2.52	N/A
Conexeu Sciences	N/A	N/A	-$3.92M	-$0.11	N/A

In the previous week, Conexeu Sciences had 1 more articles in the media than Nyxoah. MarketBeat recorded 4 mentions for Conexeu Sciences and 3 mentions for Nyxoah. Conexeu Sciences' average media sentiment score of 0.99 beat Nyxoah's score of 0.64 indicating that Conexeu Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Conexeu Sciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Conexeu Sciences has a net margin of 0.00% compared to Nyxoah's net margin of -443.16%. Conexeu Sciences' return on equity of 0.00% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-443.16%	-178.90%	-81.83%
Conexeu Sciences	N/A	N/A	N/A

Summary

Conexeu Sciences beats Nyxoah on 8 of the 12 factors compared between the two stocks.

How does Nyxoah compare to Inogen?

Nyxoah (NASDAQ:NYXH) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

In the previous week, Inogen had 2 more articles in the media than Nyxoah. MarketBeat recorded 5 mentions for Inogen and 3 mentions for Nyxoah. Nyxoah's average media sentiment score of 0.64 beat Inogen's score of 0.44 indicating that Nyxoah is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inogen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inogen has a net margin of -6.94% compared to Nyxoah's net margin of -443.16%. Inogen's return on equity of -13.17% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-443.16%	-178.90%	-81.83%
Inogen	-6.94%	-13.17%	-8.36%

89.9% of Inogen shares are held by institutional investors. 17.1% of Nyxoah shares are held by insiders. Comparatively, 2.5% of Inogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Inogen has higher revenue and earnings than Nyxoah. Inogen is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	5.54	-$101.92M	-$2.52	N/A
Inogen	$348.67M	0.44	-$22.75M	-$0.90	N/A

Nyxoah has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, Inogen has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

Nyxoah presently has a consensus target price of $5.26, suggesting a potential upside of 224.81%. Given Nyxoah's higher possible upside, research analysts plainly believe Nyxoah is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Inogen beats Nyxoah on 10 of the 17 factors compared between the two stocks.

Get Nyxoah News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NYXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NYXH vs. The Competition

Export

Metric	Nyxoah	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$61.24M	$5.95B	$7.06B	$13.10B
Dividend Yield	N/A	1.76%	2.57%	10.45%
P/E Ratio	-0.64	26.22	269.06	25.28
Price / Sales	5.54	63.09	602.43	91.76
Price / Cash	N/A	33.92	70.48	50.90
Price / Book	0.65	6.10	12.91	6.24
Net Income	-$101.92M	$148.67M	$3.45B	$347.60M
7 Day Performance	10.20%	1.84%	1.12%	1.07%
1 Month Performance	2.53%	4.56%	1.79%	1.03%
1 Year Performance	-76.18%	8.67%	67.69%	20.77%

Nyxoah Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NYXH Nyxoah	3.044 of 5 stars	$1.62 +2.5%	$5.26 +224.8%	-75.0%	$61.24M	$11.33M	N/A	110	Gap Up
RCEL Avita Medical	1.9636 of 5 stars	$8.20 +7.9%	$8.25 +0.6%	+39.1%	$233.90M	$71.61M	N/A	130
FOCL FocalTherics	2.6572 of 5 stars	$6.01 -1.2%	$9.00 +49.8%	N/A	$227.89M	$70.53M	N/A	230	News Coverage Earnings Report Analyst Forecast Gap Down
PDEX Pro-Dex	1.887 of 5 stars	$66.72 +0.7%	$70.00 +4.9%	+60.4%	$211.54M	$66.59M	23.33	140	Positive News
CNXU Conexeu Sciences	3.7396 of 5 stars	$7.44 +2.3%	$20.00 +168.8%	N/A	$194.53M	N/A	N/A	4	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NYXH) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nyxoah (NYXH) Competitors

NYXH vs. RCEL, FOCL, PDEX, CNXU, and INGN

How does Nyxoah compare to Avita Medical?

Summary

How does Nyxoah compare to FocalTherics?

Summary

How does Nyxoah compare to Pro-Dex?

Summary

How does Nyxoah compare to Conexeu Sciences?

Summary

How does Nyxoah compare to Inogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NYXH vs. The Competition

Nyxoah Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nyxoah (NYXH) Competitors

NYXH vs. RCEL, FOCL, PDEX, CNXU, and INGN

How does Nyxoah compare to Avita Medical?

Does the media favor NYXH or RCEL?

Is NYXH or RCEL more profitable?

Which has more risk & volatility, NYXH or RCEL?

Do analysts rate NYXH or RCEL?

Do institutionals and insiders believe in NYXH or RCEL?

Which has higher earnings and valuation, NYXH or RCEL?

Summary

How does Nyxoah compare to FocalTherics?

Does the media prefer FOCL or NYXH?

Which has higher earnings and valuation, FOCL or NYXH?

Is FOCL or NYXH more profitable?

Do institutionals & insiders hold more shares of FOCL or NYXH?

Which has more risk and volatility, FOCL or NYXH?

Do analysts rate FOCL or NYXH?

Summary

How does Nyxoah compare to Pro-Dex?

Does the media prefer NYXH or PDEX?

Do insiders & institutionals believe in NYXH or PDEX?

Is NYXH or PDEX more profitable?

Which has higher valuation and earnings, NYXH or PDEX?

Do analysts prefer NYXH or PDEX?

Which has more volatility & risk, NYXH or PDEX?

Summary

How does Nyxoah compare to Conexeu Sciences?

Do analysts prefer NYXH or CNXU?

Which has better valuation and earnings, NYXH or CNXU?

Does the media refer more to NYXH or CNXU?

Is NYXH or CNXU more profitable?

Summary

How does Nyxoah compare to Inogen?

Does the media favor NYXH or INGN?

Is NYXH or INGN more profitable?

Do insiders and institutionals hold more shares of NYXH or INGN?

Which has better valuation and earnings, NYXH or INGN?

Which has more volatility and risk, NYXH or INGN?

Do analysts prefer NYXH or INGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NYXH vs. The Competition

Nyxoah Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools